In case you missed it, this past week, Big Pharma giant Johnson & Johnson
reported fourth quarter earnings, beating Wall Street analysts’ expectations.





 

January 30, 2026



TOPLINE



In case you missed it, this past week, Big Pharma giant Johnson & Johnson
reported fourth quarter earnings, beating Wall Street analysts’ expectations.
The expectation-beating earnings report comes on the heels of Johnson & Johnson
hiking prices on 15 prescription drugs in its portfolio earlier this month.



During Johnson & Johnson’s fourth quarter earnings call, Joaquin Duato, chief
executive officer (CEO) of Johnson & Johnson, was bullish on continued growth
of the drug companies’ already blockbuster profits (being fueled by egregious
pricing practices and anti-competitive tactics that keep prices high for
American patients): “These moves fuel our confidence that growth in 2026 would
be faster than in 2025. And we have line of sight to double-digit growth by the
end of the decade, which is notable as Johnson & Johnson is the only healthcare
company that will soon deliver more than $100 billion in annual revenue.”
Johnson & Johnson’s earnings go hand in hand with the steady pattern of hiking
prices on blockbuster drugs.



Stay tuned to CSRxP’s Big Pharma Earnings Watch series as more reports come
out in the coming week after brand name drugmakers kicked off 2026 by raising
prices on872
<[link removed]>
prescription drugs in the first half of January, with a median increase
outpacing the rate of inflation.



Read more on Johnson & Johnson fourth quarter earnings HERE
<[link removed]>.



QUOTES OF THE WEEK



“Patients face higher prices because Big Pharma has cornered the market and
locked out new competitors.”



U.S. Senator John Hickenlooper (D-CO)
<[link removed]>



DATA POINTS YOU SHOULD KNOW



$3.4 Trillion



The amount of savings biosimilars have delivered in the last decade, according
toresearch
<[link removed]>
from the Association for Accessible Medicines.



TWEETS OF THE WEEK



@P4ADNOW <[link removed]>: “Product
hopping is just one of the many harmful tactics pharma uses to keep prices
high. By abusing the patent system, big drug companies can avoid generic and
biosimilar market competition and keep prices high. Learn how we can fight back
athttp://PatientsPushForCompetition.Org <[link removed]>”



@Runaway_Rx <[link removed]>: “Ever
wonder how drug companies keep more affordable drugs off the market? 🤔
#BigPharma games the patent system by layering many different patents onto
high-priced drugs to block affordable generic drug competition from entering
the market.”



ROAD TO RECOVERY



R Street: Coalition Letter in Support of the Biosimilar Red Tape Elimination
Act (S. 1954/H.R. 5526)
<[link removed]>



Now that there has been bicameral, bipartisan introduction of the Biosimilar
Red Tape Elimination Act by Representatives August Pfluger (R-TX) and Greg
Landsman (D-OH) (H.R. 5526) as well as Senators Mike Lee (R-UT), Ben Ray Lujan
(D-NM), Rand Paul (R-KY), and Maggie Hassan (D-NH) (S. 1954), on behalf of
patients, providers, taxpayers, and consumers, we urge you to advance this
crucial legislation. The Biosimilar Red Tape Elimination Act would remove the
distinction between biosimilars and interchangeable biosimilars. In doing so,
the legislation would increase patient access to essential biosimilar
medications and reduce healthcare costs.



AJMC: FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress
Must Finish the Job
<[link removed]>



At a moment when high drug prices continue straining families and the
healthcare system, the US finally has a clear opportunity to turn scientific
progress into real relief for millions of patients. The FDA’s October 29, 2025,
announcement of reforms to streamline biosimilar development and modernize
interchangeability is one of the most important steps yet—expanding access to
safe, effective, more affordable biologic medicines. But realizing that
potential now requires Congress to act. FDA has opened the door; policymakers
must walk through it. The US faces an escalating drug-pricing problem that
could be addressed through the increased uptake of biosimilar therapies.



PHARMA’S POOR PROGNOSIS



Reuters: Novo Nordisk Sued For Allegedly Monopolizing Diabetes Drug Victoza
<[link removed]>



Danish pharmaceutical giant Novo Nordisk was hit with a class action lawsuit
in New York federal court on Friday for allegedly misusing its patents to
maintain a monopoly on its diabetes drug Victoza. The complaint, opens new tab
from South Carolina-based drug wholesaler Smith Drug accused Novo of using a
"pay-for-delay" scheme with generic drugmaker Teva Pharmaceutical to illegally
delay cheaper generic versions of the drug. A Novo spokesperson declined to
comment on the complaint. A spokesperson and attorneys for Smith Drug did not
immediately respond to a request for comment. Spokespeople for Teva, which is
not a defendant in the lawsuit, also did not immediately respond to a request
for comment. Victoza, approved by the U.S. Food and Drug Administration in
2010, was Novo's first-generation blockbuster GLP-1 drug. The lawsuit said that
Novo sold more than $5 billion worth of the drug in the United States in 2018,
though its sales have since decreased.



Reuters: Exclusive: Novo's Wegovy And Ozempic US Advertising Spend Doubles
Rival Eli Lilly, Data Shows
<[link removed]>



Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs
Wegovy and Ozempic in the first nine months of 2025, more than double what Eli
Lilly shelled out for its rival medicines, as the Danish drugmaker fought for
market share, data seen by Reuters shows. The data from advertising tracking
firm MediaRadar, which has not been previously reported, shows Novo spent an
estimated $316 million advertising its weight-loss drug Wegovy in the U.S. and
$169 million on diabetes medication Ozempic from January through September last
year. That's up 54% and 44%, respectively from the same period in 2024.
Indianapolis-based market leader Eli Lilly spent about $131 million advertising
obesity treatment Zepbound in the same period versus $2 million in 2024. It
spent $83 million promoting diabetes medicine Mounjaro. Combined, Novo spent
about $487 million and Lilly an estimated $214 million on U.S. ads for these
drugs. The companies declined to comment on their advertising budgets.



###



























Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>